The British vaccine Astrazeneca is at the heart of the controversy, it would be at the origin of several deaths caused by cases of thrombosis. A thrombosis is a clot called also thrombus forming in a blood vessel and obstructing it. The clot can form in a vein or in an artery.
Nine new cases of atypical thrombosis (clots) and two cases of coagulation disorders associated with this vaccine, with four additional deaths, occurred in France between April 2 and 8, according to the health authorities, reports the AFP agency.
Since the start of vaccination with this vaccine, it has been “23 cases, including 8 deaths in total”, rare thrombosis and coagulation anomalies that have occurred in France, the French Medicines Agency (ANSM) said on Friday.
In total, more than 2,725,000 injections were carried out on April 8 with the Astrazeneca vaccine.
In Tunisia low doses of this vaccine have been introduced. The director of the Pasteur Institute and the head of the National COVID-9 vaccination management committee, Hechmi Louzir has announced that the doses of the Astrazeneca vaccine will be administered to people over the age of 60.
In a reassuring tone, Louzir explained that this vaccine has no effect on this age group, adding that doses will be administered during the third week of this month.
